ES2060399T3 - Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento. - Google Patents

Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento.

Info

Publication number
ES2060399T3
ES2060399T3 ES91913240T ES91913240T ES2060399T3 ES 2060399 T3 ES2060399 T3 ES 2060399T3 ES 91913240 T ES91913240 T ES 91913240T ES 91913240 T ES91913240 T ES 91913240T ES 2060399 T3 ES2060399 T3 ES 2060399T3
Authority
ES
Spain
Prior art keywords
growth hormone
hormone crystals
production
crystals
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913240T
Other languages
English (en)
Spanish (es)
Inventor
Flemming Junker
Claus Friis Theisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2060399T3 publication Critical patent/ES2060399T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES91913240T 1990-07-13 1991-07-12 Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento. Expired - Lifetime ES2060399T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK168790A DK168790D0 (OSRAM) 1990-07-13 1990-07-13

Publications (1)

Publication Number Publication Date
ES2060399T3 true ES2060399T3 (es) 1994-11-16

Family

ID=8107212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913240T Expired - Lifetime ES2060399T3 (es) 1990-07-13 1991-07-12 Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento.

Country Status (17)

Country Link
US (1) US6117984A (OSRAM)
EP (1) EP0540582B1 (OSRAM)
JP (1) JP2524446B2 (OSRAM)
AT (1) ATE110745T1 (OSRAM)
AU (1) AU666465B2 (OSRAM)
BG (1) BG61267B1 (OSRAM)
CA (1) CA2086087C (OSRAM)
DE (1) DE69103755T2 (OSRAM)
DK (2) DK168790D0 (OSRAM)
ES (1) ES2060399T3 (OSRAM)
HU (2) HUT64086A (OSRAM)
IE (1) IE67054B1 (OSRAM)
NZ (1) NZ238904A (OSRAM)
PT (1) PT98297B (OSRAM)
RU (1) RU2108341C1 (OSRAM)
WO (1) WO1992000998A1 (OSRAM)
ZA (1) ZA915446B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK168790D0 (OSRAM) * 1990-07-13 1990-07-13 Novo Nordisk As
US6894023B1 (en) * 1990-07-13 2005-05-17 Novo Nordisk A/S Growth hormone crystals and a process for production of these GH-crystals
HUT69402A (en) * 1991-12-20 1995-09-28 Novo Nordisk As Process for producing stabilized pharmaceutical formulations comprising growth hormone and histidine
SE9302278D0 (sv) * 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
KR20000057693A (ko) 1996-12-20 2000-09-25 다케다 야쿠힌 고교 가부시키가이샤 지효성 제제의 제조 방법
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US7101575B2 (en) 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US6451347B1 (en) 1999-03-01 2002-09-17 Alkermes Controlled Therapeutics, Inc. Method for purifying human growth hormone
ATE226267T1 (de) * 1999-06-10 2002-11-15 Max Planck Gesellschaft Einkapselung von kristallen mit mehrschichtigem überzug
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
ATE409465T1 (de) 2000-10-06 2008-10-15 Pacira Pharmaceuticals Inc Parenteral verabreichbare mikropartikel- zubereitung mit kontrollierter freisetzung
SE517422C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
US7105181B2 (en) 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
SE0201599D0 (sv) 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
SE0202719D0 (sv) * 2002-09-13 2002-09-13 Pharmacia Ab Process for mfg crystals of growth hormone
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
CN1744914A (zh) * 2002-12-31 2006-03-08 阿尔特斯制药公司 人生长激素晶体和制备它们的方法
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
WO2008076819A2 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA653324A (en) * 1962-12-04 G. Brink Norman Growth hormone and methods of preparing the same
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2174862A (en) * 1938-12-30 1939-10-03 Frederick Stearns & Company Process of producing crystalline insulin
US2595278A (en) * 1950-04-28 1952-05-06 Armour & Co Preparation of insulin from pancreas glands
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2897117A (en) * 1955-02-10 1959-07-28 Univ Alberta Insulin process
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
EP0343696B1 (en) * 1984-10-04 1996-01-03 Monsanto Company Zinc-associated somatotropins
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
JPS63216898A (ja) * 1987-01-30 1988-09-09 インターナシヨナル・ミネラルズ・アンド・ケミカル・コーポレイシヨン 希薄水溶液からソマトトロビンを回収する方法
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
US5109117A (en) * 1990-06-26 1992-04-28 Monsanto Company Method of somatotropin naturation using urea and a soluble organic alcohol
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
DK168790D0 (OSRAM) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
EP0540582A1 (en) 1993-05-12
RU2108341C1 (ru) 1998-04-10
BG97281A (bg) 1994-03-24
JP2524446B2 (ja) 1996-08-14
DK0540582T3 (da) 1995-01-30
HUT64086A (en) 1993-11-29
DK168790D0 (OSRAM) 1990-07-13
IE67054B1 (en) 1996-02-21
HU9300067D0 (en) 1993-04-28
DE69103755T2 (de) 1995-02-23
ATE110745T1 (de) 1994-09-15
HU210323B (en) 1995-03-28
BG61267B1 (en) 1997-04-30
JPH05507497A (ja) 1993-10-28
AU666465B2 (en) 1996-02-15
NZ238904A (en) 1993-04-28
AU8284691A (en) 1992-02-04
CA2086087C (en) 1999-09-14
DE69103755D1 (de) 1994-10-06
CA2086087A1 (en) 1992-01-14
PT98297A (pt) 1992-05-29
EP0540582B1 (en) 1994-08-31
IE912444A1 (en) 1992-01-15
PT98297B (pt) 1999-01-29
WO1992000998A1 (en) 1992-01-23
ZA915446B (en) 1992-03-25
US6117984A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
ES2060399T3 (es) Cristales de la hormona del crecimiento y procedimiento para la produccion de estos cristales de la hormona del crecimiento.
SE8504720D0 (sv) New drug preparation
ES2063013T3 (es) Procedimiento para eliminar pirogenos.
ES2108371T3 (es) Nuevos derivados de estradieno de 11-benzaldoxima, procedimientos para su produccion y farmacos conteniendo estos compuestos.
PT83872A (de) Arzneimittel
ES2059729T5 (es) Preparado farmaceutico de liberacion controlada y metodo para producir el mismo.
AT400296B (de) Dosierungsform zur schnellen abgabe eines wirkstoffes gefolgt von einer langsamen abgabe eines wirkstoffes
ES2033400T3 (es) Procedimiento para producir preparados farmaceuticos estables.
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
ATE94390T1 (de) Orale darreichungsformen mit verzoegerter abgabe.
ES2059537T3 (es) Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.
MX164474B (es) PROCEDIMIENTO PARA EL CRECIMIENTO DE CRISTAL DE MTiOXO4 DE UNA SOLUCION
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
FI872526L (fi) Menetelmä biologisesti aktiivisen plasminogeeniaktivaattorin tuottamiseksi
DK585886A (da) Immunstimulerende middel og anvendelse deraf
ES523536A0 (es) "un metodo para preparar una mezcla farmaceutica con liberacion controlada de sustancia activa"
ES2057291T3 (es) Procedimiento para la preparacion de 23-(alquilc1-c6 oxima)ll-f28249.
PT66663B (en) A method for reducing the dose of a biologically active substance while maintaining the biological effect
NO833279L (no) Farmasoeytiske preparater for behandling av uoensket sammenvoksing
ES2118728T3 (es) Procedimiento para la preparacion de 2,3-piridindicarboxilatos sustituidos y no sustituidos a partir de cloromaleato o clorofumarato o sus mezclas.
MX9102518A (es) Dicarbonatos y uretanos de acido 4,5,-dihidroxi y 4,5,8,-trihidroxi-9,10-dihidro-9,10-dioxi-2-1-antracencarboxilico que tiene actividad terapeutica.
ATE81976T1 (de) 2-pyrimidinyl-1-piperazin-derivate zur behandlung von alkoholismus.
MX9301235A (es) DERIVADOS 1,4-DIOXINO(2,3-B)PIRIDINA. á
ES2037278T3 (es) Tratamiento de la esterilidad.
ES2042529T4 (es) Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540582

Country of ref document: ES